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Background: The advantages of proximal resection with jejunal
interposition and modified D2 lymphadenectomy, for elderly
patients, could outweigh the higher risk of recurrence with this
less radical lymphadenectomy. The aim of our study was to eval-
uate proximal resection with modified D2 lymphadenectomy as
an alternative in selected patients.
Methods: Between 1993 and 2009, 161 patients at our centre
had surgery for adenocarcinoma of the proximal third of the
stomach. Patients were divided into three groups: (1) PG, proximal
resection with jejunal interposition and modified D2 lymphade-
nectomy (19.3%, 31 patients); (2) TH, transhiatal extended total
gastrectomy with resection of the distal oesophagus and D2 lym-
phadenectomy (23.6%, 38 patients); (3) GT, total gastrectomy with
D2 lymphadenectomy (57.1%, 92 patients). We analysed postoper-
ative morbidity, 30-day mortality, and survival. Quality of life was
evaluated with the gastrointestinal quality-of-life index (GIQLI)
questionnaire.
Findings: Patients in the PG group (79.4 ± 9 years) were signifi-
cantly older than the patients in the GT (63.9 ± 11 years) or TH
group (60.1 ± 12 years; p < 0.0001), and in worse general condition.
Fewer lymph nodes were harvested in the PG group (17.2 ± 11)
than in the GT and TH groups (24.05 ± 13 and 26.3 ± 13). There
were no significant differences in the distribution of pathohisto-
logical characteristics and tumour TNM stages between groups.
An R0 resection could be done in 77.2–86.8% of cases. 30-day mor-
tality was 9.7% in the PG group, 6.5% in GT, and 5.3% in TH. There
were no differences in morbidity and 5-year survival between
groups (25.3% in PG, 26.3% in GT, and 28.9% in TH). No differences
were found in the total scores of the GIQLI questionnaire
(p = 0.893). Patients in the PG group had the lowest scores in diges-
tive functions.
Interpretation: Proximal resection should be reserved for high-
risk elderly patients with proximal gastric cancer, who have
shorter expected long-term survival. These resections carry
acceptable morbidity and mortality; however, reconstruction with
jejunal interposition does not bring the desired functional
benefits.
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Background: Chemotherapy-induced neutropenia, a toxic effect
of systemic chemotherapy, is often associated with substantial
mortality and morbidity; thus, identifying its related determi-
nants is necessary. The aim of this study was to identify the main
consequences of severe neutropenia following adjuvant chemo-
therapy, in a community-based population of patients with can-
cer in Iran-Semnan.
Methods: This prospective study included 828 consecutive
patients who received chemotherapy for histologically proven
primary or metastatic solid tumours. Demographics data, disease
characteristics, and comorbidities (including current smoking
and diabetes) were collected from interviews with the patients
and their laboratory data and files. Patients had a complete blood
count 1 week after the first course of chemotherapy.
Findings: Based on the absolute neutrophil count nadir value,
30 patients (3.6%) had severe neutropenia. Multivariable
logistic-regression analysis showed that advanced age (OR =
5.262, p = 0.012) and diabetes mellitus (OR = 8.126, p = 0.015) were
main determinants of severe neutropenia, with the presence
of demographic characteristics and comorbidities as
confounders.
Interpretation: We identified advanced age and diabetes as
main determinants of high-grade neutropenia in Iranian patients
with solid tumours who were receiving adjuvant chemotherapy.
Funding: None.
The authors declared no conflicts of interest.
doi:10.1016/j.ejcsup.2011.02.017
P17 CLINICAL OUTCOMES AND PROGNOSTIC FACTORS FOR
SURGICAL TREATMENT OF ADVANCED MEDULLARY THYROID
CARCINOMA
S.H. Ma a,b, Q.J. Liu a, Y.C. Zhang b,*, R. Yang b. a Department of
General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu,
China. b Department of Head-Neck Surgical Oncology, Gansu Province
Tumor Hospital, Lanzhou, Gansu, China
Background: Total thyroidectomy and central neck dissection
are the procedures of choice for patients with medullary thyroid
carcinoma (MTC). We reviewed patients with advanced MTC
who underwent surgical treatment, to discuss the clinical out-
comes and prognostic factors.
Methods: 132 patients had total or subtotal thyroidectomy with
central neck dissection. Ipsilateral (n = 96) and bilateral (n = 36)
modified radical neck dissection was done simultaneously, in
patients with and without evidence of suspicious lymph nodes.
After surgery, basal and stimulated serum calcitonins (Cts) were
measured in all patients. Follow-up ranged between 5 and 12.5
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months. Patients were considered to be cured when stimulated Ct
was undetectable. Age, gender, tumour size, neck lymph-node
metastasis, TNM stage, extent of surgical resection, postoperative
external-beam radiation, and postoperative chemotherapy were
analysed in all patients.
Findings: Of 132 MTC patients who had locally curative surgery,
68 (51.5%) had a tumour larger than 4 cm. 92 patients (69.7%) were
biochemically cured and 76 (57.6%) cases involved lymph-node
metastasis. Biochemical cure was significantly correlated with
extrathyroid extension (p < 0.005), tumour size (p < 0.005), and
lymph-node metastases (p < 0.0001). The 5-year and 10-year can-
cer-specific cumulative survival rates were 73.4% and 19.6%,
respectively. In univariate analysis, age and the presence of node
metastases were significant prognostic factors. Only age
remained an independent prognostic factor in multivariate
analysis.
Interpretation: Clinical outcome is significantly better for MTC
patients younger than 45 years, regardless of tumour size and
node metastases. The younger age at diagnosis and modified rad-
ical neck dissection might enhance the outcome. Age was a
unique independent prognostic factor. Patients with MTC should
be regarded as having systemic disease; and patients with a
tumour larger than 4.0 cm, bilateral neck node metastases, and
accompanying systemic symptoms are unlikely to be biochemi-
cally cured, even with extensive surgery.
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Background: Trastuzumab has revolutionised the way we treat
early, HER2/neu-positive breast cancer, because it significantly
improves disease-free and overall survival. Little is known about
the societal costs and benefits of treatment with trastuzumab in
the adjuvant setting in Asia. This study aimed to be the first eco-
nomic evaluation of trastuzumab in Singapore and Asia, assess-
ing its net economic gains to society.
Methods: An analytic model was used to estimate societal costs
(and benefits) of treatment with trastuzumab in Singapore. Direct
costs were derived from actual patient costs at four treatment
centres in Singapore – two private and two public centres, com-
prising 60–70% of all patients with cancer. Indirect costs were
assessed as the loss of productivity caused by the disease or treat-
ment. Benefits to society were based on extra years of productiv-
ity (measured by GNI per capita) resulting from the quality-
adjusted life-years (QALY) saved with the use of trastuzumab, as
determined in the models by Kurian (J Clin Oncol 2007), Liberato
(J Clin Oncol 2007), and Garrison (Cancer 2007). Sensitivity analysis
was performed.
Findings: Incremental costs in Singapore were $26,971.05 (all
costs are in 2005 US dollars). The average cost per QALY was
$19,174.59 (median $18,993.70). Costs (benefits) to society ranged
from a cost of $79.42 to a benefit of $9,263.06 per person, depend-
ing on the model used (average benefit $4,375.89, median
$3,944.03). Sensitivity analysis ranged from a cost of $10,685.00
to a benefit of $17,298.79.
Interpretation: Treatment with adjuvant trastuzumab is likely
to generate net societal economic benefits in Singapore. Never-
theless, the lower range of possible outcomes does not refute
the possibility that treatment may actually generate costs; how-
ever, these costs fall within the range of acceptable cost-
effectiveness.
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Background: To develop standardised and well-rounded mate-
rial for hepatology research.
Methods: The National Liver Tissue Bank (NLTB) project began
in China in 2008, to make well-characterised and optimally pre-
served liver tumour tissue available and to create a clinical
database.
Findings: From December, 2008, to June, 2010, more than 3000
individuals enrolled at the NLTB as liver tumour donors, includ-
ing 2317 cases of newly diagnosed hepatocellular carcinoma
(HCC), and about 1000 cases diagnosed as benign or malignant
liver tumours. The clinical database and sample store can be
managed easily and correctly with the data management plat-
form used.
Interpretation: We believe that the high-quality samples and
database with detailed information will become the cornerstone
of hepatology research, particularly in studies of diagnosis and
new treatments for HCC and other liver disease.
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